Compare Amylx Pharmaceuticals Inc (AMLX) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.67 (market cap $2.64B), while Booz Allen Hamilton Holding Corporation trades at $78.22 (market cap $9.45B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 3.6× Amylx Pharmaceuticals Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BAH | |
|---|---|---|
Market Cap | $2.64B | $9.45B |
Sector | Health | Industrials |
52-Week High | $24.19 | $111.63 |
52-Week Low | $7.82 | $59.71 |
Enterprise Value | $2.39B | $13.07B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Booz Allen Hamilton (BAH) trades at $77.93, up 0.04% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 7.01% net margin and 68.11% ROE, while valuation ratios like P/E of 12.33 and P/S of 0.86 appear attractive. Recent Q2 2026 earnings beat estimates at $1.81 per share, and the company maintains consistent dividend payments, reflecting financial stability.
Outlook remains positive with analyst consensus price target of $84.67, though risks include high debt levels and civil revenue weakness. Growth in national security and AI investments offers upside, but investors should monitor leverage and sector-specific headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
